255 related articles for article (PubMed ID: 10999734)
1. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
2. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Krug LM; Azzoli CG; Kris MG; Miller VA; Khokhar NZ; Tong W; Ginsberg MS; Venkatraman E; Tyson L; Pizzo B; Baez V; Ng KK; Sirotnak FM
Clin Cancer Res; 2003 Jun; 9(6):2072-8. PubMed ID: 12796370
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
5. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
6. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer.
Ichiki M; Gohara R; Fujiki R; Hoashi S; Rikimaru T; Aizawa H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):67-72. PubMed ID: 12743738
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
15. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
18. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
19. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]